SUPPLEMENTAL MATERIAL

Supplemental figure I



Supplemental figure I. Mitochondrial membrane potential assessment using JC1. **A.** Measurement of background signal of various concentration of JC1. JC1 (1 μM) was used in overall measurement. **B.** JC1 measurement after excluding all mitochondria by 100-kDa membrane filter confirmed significant reduction of JC1 green and red signals (n=5). **C.** JC1 measurement after freezing and thawing human CSF samples (n=15).

Supplemental figure II



R square = 0.219897
R = 0.4689
P = 0.0078



R square = 0.276749
R = 0.5261
P = 0.0005



R square = 0.161188
R = 0.4015
P = 0.0102

Supplemental figure II. Negative correlation of CSF JC1 value with age after SAH.
CSF JC1 value was negatively correlated with age at days 1, 3, and 5 after SAH.

Stroke Online Supplement

Table I. Checklist of Methodological and Reporting Aspects for Articles Submitted to *Stroke* Involving Preclinical Experimentation

Methodological and Reporting Aspects	Description of Procedures
Experimental groups and study timeline	☑ The experimental group(s) have been clearly defined in the article, including number of animals in each experimental arm of the study. ☑ An account of the control group is provided, and number of animals in the control group has been reported. If no controls were used, the rationale has been stated. ☑ An overall study timeline is provided.
Inclusion and exclusion criteria	☑ A priori inclusion and exclusion criteria for tested animals were defined and have been reported in the article.
Randomization	☑ Animals were randomly assigned to the experimental groups. If the work being submitted does not contain multiple experimental groups, or if random assignment was not used, adequate explanations have been provided. ☑ Type and methods of randomization have been described. ☑ Methods used for allocation concealment have been reported.
Blinding	☑ Blinding procedures have been described with regard to masking of group/treatment assignment from the experimenter. The rationale for nonblinding of the experimenter has been provided, if such was not feasible. ☐ Blinding procedures have been described with regard to masking of group assignment during outcome assessment.
Sample size and power calculations	☑ Formal sample size and power calculations were conducted based on a priori determined outcome(s) and treatment effect, and the data have been reported. A formal size assessment was not conducted and a rationale has been provided.
Data reporting and statistical methods	☑ Number of animals in each group: randomized, tested, lost to follow-up, or died have been reported. If the experimentation involves repeated measurements, the number of animals assessed at each time point is provided, for all experimental groups. ☑ Baseline data on assessed outcome(s) for all experimental groups have been reported. ☑ Details on important adverse events and death of animals during the course of experimentation have been provided, for all experimental arms. ☑ Statistical methods used have been reported. ☑ Numeric data on outcomes have been provided in text, or in a tabular format with the main article or as supplementary tables, in addition to the figures.
Experimental details, ethics, and funding statements	☑ Details on experimentation including stroke model, formulation and dosage of therapeutic agent, site and route of administration, use of anesthesia and analgesia, temperature control during experimentation, and postprocedural monitoring have been described. ☑ Different sex animals have been used. If not, the reason/justification is provided. ☑ Statements on approval by ethics boards and ethical conduct of studies have been provided. ☑ Statements on funding and conflicts of interests have been provided.